Research programme: protein therapeutics - Complix

Drug Profile

Research programme: protein therapeutics - Complix

Alternative Names: Alphabodies; Alphabody; Anti-MCL1 alphabody; Cell-penetrating alphabodies; CMPX 1023; CMX-02; CPABs - Complix

Latest Information Update: 27 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Complix
  • Class Proteins
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Interleukin-23 subunit p19 modulators; MCL1 protein modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Viral infections

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders; CNS disorders; Metabolic disorders; Viral infections

Most Recent Events

  • 29 Nov 2016 Protein therapeutics are still in preclinical trials for Cancer in Belgium
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Belgium (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Belgium (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top